NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Prospective Study of Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

20-C-0161

Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 6 Years
Max Age: N/A

Referral Letter Required

No

Population Exclusion(s)

None

Keywords

Tyrosine Kinase Inhibitor (TKI) Therapy;
Wild-Type GISTs (WT GISTs);
PDGFRA Mutation;
KIT Mutation;
SDH Mutation;
Natural History

Recruitment Keyword(s)

None

Condition(s)

Gastric Cancer;
Gastric Neoplasm;
Gastrointestinal Stromal Sarcoma;
Gastrointestinal Stromal Neoplasm;
Gastrointestinal Stromal Tumor (GIST)

Investigational Drug(s)

None

Investigational Device(s)

None

Intervention(s)

None

Supporting Site

National Cancer Institute

Objective:

To follow people with GISTs and collect tumor tissue so that it can be studied in the lab.

Eligibility:

People age 6 and older who have a GIST.

Design:

Participants will be screened with a review of their medical records and samples.

Participants will enroll in 1 other NIH study, and may be asked to enroll in 2 other optional NIH studies.

Participants will have a medical history and physical exam. Data about how they function in their daily activities will be obtained.

Participants may speak with a genetic counselor. They may have genetic testing.

Participants will give blood samples. They may have a cheek swab. For this, small brush will be rubbed against the inside of the cheek.

Participants may have a computed tomography (CT) scan of the chest, abdomen, and pelvis. Or they may have a CT scan of the chest and magnetic resonance imaging (MRI) of the abdomen and pelvis.

Participants will be monitored every 6-12 months at the NIH Clinical Center, for up to 10 years before having surgery. If they need surgery, it will be performed at the NIH. Then, they will be monitored every 6-12 months, for up to 5 years after surgery.

If a participant has surgery, tumor tissue samples will be taken.

If a participant does not need surgery, their participation will end after 10 years. If they have surgery, the 5-year monitoring period will restart after each surgery.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

- Histological confirmation or clinical presentation suspicious of GIST; histological confirmation will be preferably by review of archival tissue if available, fresh biopsy will not be required if inadequate tissue sample.

- Age >= 6 years

- ECOG performance status <= 2 (Karnofsky or Lansky >= 60%)

- Ability of participant or parent/guardian to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

- Non-modifiable medical comorbidities that would preclude cytoreductive surgery.


--Back to Top--

Citations:

Not Provided

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Andrew M. Blakely, M.D.
National Cancer Institute (NCI)
NIHBC 10 - CRC BG RM 4-3760B
10 CENTER DR
BETHESDA MD 20892
(240) 760-7647
andrew.blakely@nih.gov

Audra A. Satterwhite, R.N.
National Cancer Institute (NCI)
National Institutes of Health
Building 10
Room 4W5920
10 Center Drive
Bethesda, Maryland 20892
(240) 858-3552
audra.satterwhite@nih.gov

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office
1-888-NCI-1937
ncimo_referrals@mail.nih.gov

Clinical Trials Number:

NCT04557969

--Back to Top--